Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities

Table 3 Ongoing studies with tivantinib

NCT Number	Combination Drugs	PHASES	URL
NCT01755767	Drug:Tivantinib	Phase 3	https://ClinicalTrials.gov/show/NCT01755767
NCT01755767	Drug: Placebo	Phase 3	https://ClinicalTrials.gov/show/NCT01755767
NCT00988741	Drug: ARQ 197	Phase 2	https://ClinicalTrials.gov/show/NCT00988741
NCT00988741	Drug: Placebo	Phase 2	https://ClinicalTrials.gov/show/NCT00988741
NCT01656265	Drug: ARQ 197	Phase 1	https://ClinicalTrials.gov/show/NCT01656265
NCT00802555	Drug: ARQ 197	Phase 1	https://ClinicalTrials.gov/show/NCT00802555
NCT00557609	Drug: ARQ 197	Phase 2	https://ClinicalTrials.gov/show/NCT00557609
NCT01575522	Other: Laboratory Biomarker Analysis	Phase 2	https://ClinicalTrials.gov/show/NCT01575522
NCT01575522	Drug: Tivantinib	Phase 2	https://ClinicalTrials.gov/show/NCT01575522
NCT01395758	Drug: ARQ 197 plus erlotinib	Phase 2	https://ClinicalTrials.gov/show/NCT01395758
NCT01395758	Drug: Pemetrexed, docetaxel or gemcitabine	Phase 2	https://ClinicalTrials.gov/show/NCT01395758
NCT01244191	Drug: Tivantinib	Phase 3	https://ClinicalTrials.gov/show/NCT01244191
	Drug: Placebo
	Drug: Erlotinib
NCT01069757	Drug: ARQ 197 and Erlotinib	Phase 1	https://ClinicalTrials.gov/show/NCT01069757
NCT01251796	Drug: ARQ 197 and Erlotinib	Phase 1	https://ClinicalTrials.gov/show/NCT01251796
NCT00777309	Drug: ARQ 197	Phase 2	https://ClinicalTrials.gov/show/NCT00777309
	Drug: Erlotinib
	Drug: Placebo

ISSN: 1476-4598